The taxman has been forced into a tactical retreat over a contentious VAT levy on free medicines supplied to seriously ill patients, after Britain’s pharmaceutical heavyweights warned the policy was jeopardising the country’s standing as a global life sciences hub.
HM Revenue & Customs has confirmed to the industry that it will pause enforcement of disputed VAT bills issued against drugs companies providing medicines free of charge under early access programmes, while Whitehall thrashes out a longer-term settlement with the sector.
The climbdown follows mounting alarm in boardrooms after Bayer, the German pharmaceutical multinational, took the unprecedented step last month of halting new patient enrolments under its UK compassionate use scheme. *Business Matters* understands that at least one further major drugmaker is now actively weighing a similar withdrawal, raising the spectre of vulnerable patients being denied cutting-edge therapies.
At the heart of the dispute are post-clinical trial continuity of care and compassionate use schemes, arrangements designed to bridge the gap for patients with life-threatening or severely debilitating conditions who require access to medicines that have yet to secure marketing authorisation or NHS funding. For many of these patients, the schemes represent a clinical lifeline.
HMRC had begun issuing VAT demands to pharma companies on the basis that supplying these medicines, even gratis, constituted a taxable transaction. Industry leaders have argued the interpretation is not only commercially punishing but threatens to undermine the UK’s hard-won reputation as a destination of choice for clinical research, a sector ministers have repeatedly identified as central to the government’s growth ambitions.
The Association of the British Pharmaceutical Industry has been pressing ministers to confirm that “clinically justified” free-of-charge supply should fall outside the scope of VAT altogether. Without that assurance, executives warn, multinational sponsors will simply route their next generation of trials to more accommodating jurisdictions.
Following a recent meeting between Treasury officials and pharma chief executives, HMRC policy officials have informed the industry that, while the agency retains an obligation to protect Exchequer revenue, it accepts the government is “actively considering” the issue. The taxman has therefore agreed to exercise its discretion by extending review periods and holding off on enforcement action while talks continue. Crucially, however, HMRC has not budged on its view of historic tax liabilities, meaning bills already issued remain on the table.
A Whitehall source insisted that no blanket reprieve was on offer, with each case being assessed individually. “HMRC is not systemically extending review periods,” the source said.
The political temperature has been rising for months. Julia Lopez, the shadow science, innovation and technology secretary, wrote to Liz Kendall, her opposite number, in February warning that “the UK’s reputation as a home for clinical research is essential to our status as a life sciences superpower. That reputation is now at risk.”
In a reply this month, Lord Vallance, the science minister and a former senior executive at GSK, acknowledged ministers were “aware of the issue” and recognised “the importance of patients across the UK having access to innovative medicines.” He confirmed the government was in “discussions with the sector on this matter” and added: “I fully recognise the concerns you have raised.”
Bayer, in announcing its decision to suspend new enrolments, said it had been supplying treatments to patients with “life-threatening, long-lasting, or severely debilitating conditions or diseases which cannot satisfactorily be treated by any licensed and reimbursed drug in the UK.” Following the change in HMRC’s stance, the company said it had “made the difficult decision to pause the addition of new patients” while continuing to serve those already enrolled.
The Treasury maintains that “in certain circumstances the giving of goods away for free can be outside the scope of VAT,” and that where supply does fall within scope, a relief may apply. A government spokesperson said: “We are in active discussions with the sector. We fully recognise the importance of early access and compassionate use schemes and are fully committed to ensuring patients can continue to benefit from them.” A government source added that there had been no recent changes to UK VAT policy.
Lopez was unconvinced. “Even if HMRC has paused this damaging VAT charge, and it’s still not clear, the harm has already begun,” she said.
For an industry that contributes more than £17bn annually to the British economy and employs tens of thousands in high-skilled research roles, the affair has crystallised wider anxieties about the predictability of the UK tax environment. With the government banking heavily on life sciences as an engine of post-Brexit growth, ministers will be acutely conscious that a swift and unambiguous resolution is now needed — not least to reassure the international boardrooms where the next round of investment decisions is already being weighed.
Read more:
HMRC backs down on free-drugs VAT raid as pharma giants threaten UK exodus
